Challenges in the treatment of HIV and HCV coinfection

Expert Review of Clinical Immunology

Volumn 2, Issue 5, 2006, Pages 811-822

  Streeck, Hendrik ^b   Rockstroh, Jürgen K ^a,b  

^a UNIVERSITY OF BONN   (Germany)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Coinfection; HCV; HIV; PEG IFN; Therapy

Indexed keywords

EID: 57349105855     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2.5.811     Document Type: Review

References (72)

1. Rockstroh JK, Mocroft A, Soriano V et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J. Infect. Dis. 192, 992-1002 (2005). (Pubitemid 41266795)
2. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin. Infect. Dis. 34, 831-837(2002). (Pubitemid 34194855)
3. Ockenga J, Tillmann HL, Trautwein C, Stoll M, Manns MP, Schmidt RE. Hepatitis B and C in HIV-infected patients. Prevalence and prognostic value. J. Hepatol. 27, 18-24(1997). (Pubitemid 27357049)
4. Saillour F, Dabis F, Dupon M et al. Prevalence and determinants of antibodies to hepatitis C virus and markers for hepatitis B virus infection in patients with HIV infection in Aquitaine. Groupe d'Epidemiologie Clinique du SIDA en Aquitaine. Br. Med. J. 313, 461-464 (1996). (Pubitemid 26280351)
5. Browne R, Asboe D, Gilleece Y et al. Increased numbers of acute hepatitis C infections in HIV positive homosexual men: is sexual transmission feeding the increase? Sex. Transm. Inject. 80, 326-327 (2004). (Pubitemid 39070800)
6. Gambotti L, Batisse D, Colin-de-Verdiere N et al. Acute hepatitis C infection in HIV positive men who have sex with men in Paris, France. Euro. SurveilL 10, 115-117(2001).
7. Zanetti AR, Tanzi E, Paccagnini S et al. Mother-to-infant transmission of hepatitis C virus. Lombardy Study Group on Vertical HCV Transmission. Lancet 345, 289-291 (1995).
8. Soto B, Sanchez-Quijano A, Rodrigo L et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J. Hepatol 26, 1-5 (1997). (Pubitemid 27072597)
9. Eyster ME, Diamondstone LS, Lien JM, Ehmann WC, Quan S, Goedert JJ. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus. The Multicenter Hemophilia Cohort Study, J. AIDS6, 602-610 (1993). (Pubitemid 23186101)
10. Graham CS, Baden LR, Yu E et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin. Infect. Dis. 33, 562-569 (2001). (Pubitemid 32709592)
11. Telfer P, Sabin C, Devereux H, Scott F, Dusheiko G, Lee C. The progression of HCV-associated liver disease in a cohort of haemophilic patients. Br. J. Haematol. 87, 555-561 (1994). (Pubitemid 24230022)
12. Cribier B, Rey D, Schmitt C, Lang JM, Kirn A, Stoll-Keller F. High hepatitis C viraemia and impaired antibody response in patients coinfected with HIV. AIDS 9, 1131-1136(1995).
13. Sherman KE, O'Brien J, Gutierrez AG et al. Quantitative evaluation of hepatitis C virus RNA in patients with concurrent human immunodeficiency virus infections. J. Clin. Microbiol. 31, 2679-2682 (1993). (Pubitemid 23284901)
14. Bonacini M, Redeker AG. Intrahepatic HCV levels in chronic HCV infection. Gut 45, 630-631(1999). (Pubitemid 29447840)
15. Monga HK, Rodriguez-Barradas MC, Breaux K et al. Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin. Infect. Dis. 33, 240-247 (2001). (Pubitemid 32643340)
16. Rockstroh JK, Spengler U, Sudhop let al. Immunosuppression may lead to progression of hepatitis C virus-associated liver disease in hemophiliacs coinfected with HIV. Am. J. Gastroenterol 91, 2563-2568 (1996).
17. Rosenthal E, Poiree M, Pradier C et al. Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic study). AIDS 17, 1803-1809 (2001).
18. Sanchez-Quijano A, Andreu J, Gavilan F et al. Influence of human immunodeficiency virus type 1 infection on the natural course of chronic parenterally acquired hepatitis C. Eur. J. Clin. Microbiol. Infect. Dis. 14, 949-953 (1995).
19. Garcia-Samaniego J, Rodriguez M, Berenguer J et al. Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am. J. Gastroenterol. 96, 179-183 (2001). (Pubitemid 32104826)
20. Pineda JA, Romero-Gomez M, Diaz-Garcia F et al. HIV coinfection shortens the survival of patients with hepatitis C virus-telated decompensated cirrhosis. Hepatology 41, 779-789 (2005). (Pubitemid 40462940)
21. Benhamou Y, Bochet M, Di Martino V et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 30, 1054-1058 (1999). (Pubitemid 29458296)
22. Daar ES, Lynn H, Donfield S et al. Hepatitis C virus load is associated with human immunodeficiency virus type 1 disease progression in hemophiliacs, J. Infect. Dis. 183, 589-595(2001). (Pubitemid 32147515)
23. Dorrucci M, Pezzotti P, Phillips AN, Lepri AC, Rezza G. Coinfection of hepatitis C virus with human immunodeficiency virus and progression to AIDS. Italian Seroconversion Study. J. Infect. Dis. 172, 1503-1508 (1995).
24. Staples CT Jr, Rimland D, Dudas D. Hepatitis C in the HIV (human immunodeficiency virus) Adanta VA. (Veterans Affairs Medical Center) Cohort Study (HAVACS): the effect of coinfection on survival. Clin. Infect. Dis. 29, 150-154 (1999). (Pubitemid 29336817)
25. Greub G, Ledergerber B, Battegay M et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-I and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 356, 1800-1805 (2000).
26. Piroth L, Grappin M, Cuzin L et al. Hepatitis C virus coinfection is a negative prognostic factor for clinical evolution in human immunodeficiency virus-positive patients. J. Viral Hepat. 7, 302-308 (2000).
27. Kaufmann GR, Perrin L, Pantaleo G et al. CD4T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch. Intern. Med. 163, 2187-2195 (2003). (Pubitemid 37248783)
28. Rockstroh JK. Influence of viral hepatitis on HIV infection. J. Hepatol 44, S25-S27 (2006). (Pubitemid 43053869)
29. Soriano V, Puoti M, Sulkowski M et al. Care of patients with hepatitis C and HIV coinfection. AIDS 18, 1-12 (2004). (Pubitemid 38402312)
30. Flamm SL. Chronic hepatitis C virus infection. JAMA 289, 2413-2417 (2003). (Pubitemid 37430175)
31. Trimoulet P, Neau D, Le Bail B et al. Intrahepatic HCV RNA loads in HIV-HCV co-infected patients with controlled HIV infection. J. Med. Virol 67, 143-151 (2002). (Pubitemid 34493428)
32. Nelson M, Matthews G, Brook MG, Main J. BHIVA guidelines on HIV and chronic hepatitis: coinfection with HIV and hepatitis C virus infection. HIV Med. 6(Suppl. 2), 96-106 (2005). (Pubitemid 41038588)
33. Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 35, 182-189 (2002). (Pubitemid 34032559)
34. Martinez E, Blanco JL, Arnaiz JA et al. Hepatotoxicity in HIV-I-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 15, 1261-1268(2001). (Pubitemid 32592358)
35. Puoti M, Bonacini M, Spinetti A et al. Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus. J. Infect. Dis. 183, 134-137(2001). (Pubitemid 32043052)
36. Brau N, Salvatore M, Rios-Bedoya CF et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J. Hepatol 44, 47-55 (2006). (Pubitemid 41772515)
37. Tural C, Fuster D, Tor J et al. Time on antiretroviral therapy is a protective factor for liver fibrosis in HIV and hepatitis C virus (HCV) co-infected patients. J. Viral Hepat. 10, 118-125(2003). (Pubitemid 36359849)
38. Mehta S, Thomas D, Torbenson M et al. The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection. Hepatology 41, 123-131 (2005). (Pubitemid 40066390)
39. Qurishi N, Kreuzberg C, Luchters G et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 362, 1708-1713 (2003). (Pubitemid 37468321)
40. Bonacini M, Louie S, Bzowej N, Wohl AR. Survival in patients with HIV infection and viral hepatitis B or C: a cohort study. AIDS 18, 2039-2045 (2004). (Pubitemid 39463357)
41. Merchante N, Giron-Gonzalez JA, Gonzalez-Serrano M et al. Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease. AIDS 20, 49-57 (2006). (Pubitemid 41818114)
42. Braitstein P, Palepu A, Dieterich D, Benhamou Y, Montaner JS. Special considerations in the initiation and management of antiretroviral therapy in individuals coinfected with HIV and hepatitis C. AIDS 18, 2221-2234 (2004). (Pubitemid 39620214)
43. Chung RT. Acute hepatitis C virus infection. Clin. Infect. Dis. 41(Suppl. 1), S14-S17 (2005). (Pubitemid 40863720)
44. Chung RT, Andersen J, Volberding P et al. Peginterferon A-2a plus ribavirin versus interferon a-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N. Engl. J. Med. 351, 451-459 (2004). (Pubitemid 38988594)
45. Torriani FJ, Rodriguez-Torres M, Rockstroh JK et al. Peginterferon a-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N. Engl. J. Med. 351, 438-450 (2004). (Pubitemid 38988593)
46. Carrat F, Bani-Sadr F, Pol S et al. Pegylated interferon a-2b vs standard interferon α-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 292, 2839-2848 (2004). (Pubitemid 39628231)
47. Laguno M, Murillas J, Blanco JL et al Peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 18, F27-F36 (2004). (Pubitemid 39179626)
48. Cargnel A, Angeli E, Mainini A et al. Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART. Antivir. Ther. 10, 309-317 (2005). (Pubitemid 41151037)
49. Arends JE, Boucher CA Hoepelman AI. Hepatitis C virus and human immunodeficiency virus coinfection: where do we stand? Neth. J. Med 63, 156-163 (2005). (Pubitemid 40796683)
50. Vogt MW, Hartshorn KL, Furman PA et al Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science 235, 1376-1379(1987). (Pubitemid 17041656)
51. Gries J, Torriani F, Rodriguez-Torres M et al Effect of ribavirin on intracellular and plasma pharmacokinetics of nucleoside reverse transcriptase inhibitors in patients with HCV/HIV coinfection: final results of a randomized clinical study. Antimicrob. Agents Chemother. 49(10), 3997-4008 (2005). (Pubitemid 41400938)
52. Nunez M, Miralles C, Berdun M et al. The PRESCO study: role of extended therapy and/or optimal doses of ribavirin in the treatment of chronic hepatitis C in HIV-infected patients. 46th Inter Science Conference on Antimicrobial Agents and Chemotherapy. CA, USA, September 27-30 (2006) (In Press).
53. Pcrez-Olmeda M, Nunez M, Romero M et al. Pegylated IFN-a2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS 17, 1023-1028 (2003). (Pubitemid 36549714)
54. Voigt E, Schulz C, Klausen G et al. Pegylated interferon α-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-coinfected patients, J. Infect. 53, 36-42 (2006). (Pubitemid 43960441)
55. Dieterich D, Duff F, Sulkowski M et al. Sustained virologie response (SVR) in HIV-HCV co-infected patients with HCV genotype 1(G1) infection who have a rapid virological response (RVR) at week 4 of treatment with peginterferon α-2a (40KD) (PEG IFNa-2a, PEGASYS®) plus ribavirin (RBV, COPEGUS®): AIDS PEGASYS ribavirin international coinfection trial (APRICOT). 13th Conference on Retroviruses and Opportunistic Infections. CO, USA, February 5-8 (2006).
56. Crespo M, Esteban J, Ribera E et al. Utility of the early virological response to individually adjust the duration of treatment for chronic hepatitis C, genotype 2 or 3, in HIV-coinfected patients. 13th Conference on Retroviruses and Opportunistic Infections. CO, USA, February 5-8 (2006).
57. Zanini B, Puoti M, Quiros Roldan E et al. The optimal duration of treatment for HIV-infected patients with chronic hepatitis C (CHC) and genotype 2 or 3 is 48 weeks: results of a randomised controlled trial. 3rd IAS Conference on HIV Pathogenesis and Treatment. Rio De Janeiro, Brazil, July 24-27 (2005).
58. Buti M, Valdes A, Sanchez-Avila F, Esteban R, Lurie Y. Extending combination therapy with peginterferon α-2b plus ribavirin for genotype 1 chronic hepatitis C late responders: a report of 9 cases. Hepatology 37, 1226-1227 (2003). (Pubitemid 36538703)
59. Berg T, von Wagner M, Nasser S et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-a-2a plus ribavirin. Gastroenterology 130, 1086-1097 (2006).
60. Fontana RJ. Optimizing outcomes in hepatitis C: is treatment beyond 48 weeks ever justified? Gastroenterology 130, 1357-1362(2006).
61. Shiffman M, Pappas S, Nyberg L et al. Peginterferon α-2a (PEGASYS) plus ribavirin (COPEGUS) for 16 or 24 weeks in patients with HCV genotype 2 or 3. Final results of the ACCELERATE trial. 41st Annual Meeting of the European Association for the Study of the Liver (41st EASL). Vienna, Austria, April 26-30 (2006).
62. Alberti A, Clumeck N, Collins S et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV coinfected patients. J. Hepatol. 42, 615-624 (2005).
63. Bani-Sadr F, Carrat F, Bedossa P et al. Hepatic steatosis in HIV-HCV coinfected patients: analysis of risk factors. AIDS 20, 525-531 (2006). (Pubitemid 43731596)
64. Haas DW, Lavelle J, Nadler JP et al. A randomized trial of interferon a therapy for HIV type 1 infection. AIDS Res. Hum. Retroviruses 16, 183-190 (2000). (Pubitemid 30111954)
65. Soriano V, Sulkowski M, Bergin C et al. Care of patients with chronic hepatitis C and HIV coinfection: recommendations from the HIV-HCV International Panel. AIDS 16, 813-828 (2002). (Pubitemid 34409005)
66. Bacon BR. Treatment of patients with hepatitis C and normal serum aminotransferase levels. Hepatology 36, S179-S184 (2002). (Pubitemid 35253479)
67. Maida I, Soriano V, Gonzalez Lahoz J, Nunez M. Liver fibrosis stage in HIV/HCV-coinfected patients with persistently normal transaminases levels. 45th International Conference on Antimicrobial Agents and Chemotherapy. Washington DC, USA, December 16-19 (2005).
68. Castera L, Vergniol J, Foucher J et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 128, 343-350 (2005). (Pubitemid 40439195)
69. Colletta C, Smirne C, Fabris C et al. Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases. Hepatology 42, 838-845 (2005). (Pubitemid 41401121)
70. Saito H, Tada S, Nakamoto N et al. Efficacy of non-invasive elastometry on staging of hepatic fibrosis. Hepatol. Res. 29, 97-103 (2004). (Pubitemid 38667506)
71. Macias J, Giron-Gonzalez JA, Gonzalez-Serrano M et al Prediction of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfected patients by simple non-invasive indexes. Gut 55, 409-414 (2006). (Pubitemid 43268282)
72. Nunes D, Fleming C, Offner G et al. HIV infection does not affect the performance of noninvasive markers of fibrosis for the diagnosis of hepatitis C virus-related liver disease. J. Acquir. Immune. Defic. Syndr. 40, 538-544 (2005). (Pubitemid 41669157)